{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:44Z","timestamp":1791262364601,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["464568473"],"award-info":[{"award-number":["464568473"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anai.2026.08.033","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:19:57Z","timestamp":1788362397000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement C5 defines 2 chronic spontaneous urticaria endotypes with distinct autoantibody profiles and omalizumab responses: The INCA study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-8847","authenticated-orcid":false,"given":"Jo\u00e3o Lu\u00eds Alves","family":"Marcelino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Pashuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-kui","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Scheffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Sofia Pires de Aguiar","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico Eug\u00e9nio de Castro Soares","family":"Regateiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria P\u00eago","family":"Todo-Bom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor Ros\u00e1rio Carneiro","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Miguel Teixeira","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben Duarte","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Dias dos Santos Ferreira","family":"Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Filipa Marques","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elza","family":"Tomaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melba","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.anai.2026.08.033_bib0001","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/all.16243","article-title":"Disease modification in chronic spontaneous urticaria","volume":"79","author":"Maurer","year":"2024","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.anai.2026.08.033_bib0002","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3390\/cells10071759","article-title":"The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria","volume":"10","author":"Yanase","year":"2021","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.anai.2026.08.033_bib0003","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/all.70210","article-title":"The international guideline for the definition, classification, diagnosis and management of urticaria","volume":"81","author":"Zuberbier","year":"2026","journal-title":"Allergy."},{"issue":"4","key":"10.1016\/j.anai.2026.08.033_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15586\/aei.v53i4.1443","article-title":"Biomarkers of response to omalizumab in patients with chronic spontaneous urticaria","volume":"53","author":"Akta\u015f","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.anai.2011.09.008","article-title":"Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria","volume":"108","author":"Mathias","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.08.033_bib0006","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2026.08.033_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210320","article-title":"Basophil characteristics as a marker of the pathogenesis of chronic spontaneous urticaria in relation to the coagulation and complement systems","volume":"24","author":"Yanase","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anai.2026.08.033_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.994823","article-title":"Basophils activation of patients with chronic spontaneous urticaria in response to C5a despite failure to respond to IgE-mediated stimuli","volume":"13","author":"Matsubara","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.08.033_bib0009","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa","volume":"11","author":"Xiang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0091-6749(99)70129-6","article-title":"Complement dependence of histamine release in chronic urticaria [published correction in J Allergy Clin Immunol. 2000;105;2(1):392]","volume":"104","author":"Ferrer","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0011","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1067\/mai.2002.120954","article-title":"A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria","volume":"109","author":"Kikuchi","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.08.033_bib0012","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cei.13428","article-title":"Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria","volume":"200","author":"Asero","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.anai.2026.08.033_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2026.05.002","article-title":"Endotypes in chronic spontaneous urticaria","author":"Kaplan","year":"2026","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2026.08.033_bib0014","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188352","article-title":"Complement\u2019s involvement in allergic Th2 immunity: a cross-barrier perspective","volume":"135","author":"Thomas","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2026.08.033_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1007102","article-title":"Pitfalls in complement analysis: a systematic literature review of assessing complement activation","volume":"13","author":"Brandwijk","year":"2022","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.anai.2026.08.033_bib0016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cll.2019.07.006","article-title":"Analysis of the complement system in the clinical immunology laboratory","volume":"39","author":"Ling","year":"2019","journal-title":"Clin Lab Med"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0017","first-page":"43","article-title":"Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria","volume":"31","author":"Zhu","year":"2013","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.08.033_bib0018","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jaci.2020.08.018","article-title":"Coagulation factors induce human skin mast cell and basophil degranulation via activation of complement 5 and the C5a receptor","volume":"147","author":"Yanase","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.08.033_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12011","article-title":"Systemic and local evidence for complement involvement in chronic spontaneous urticaria","volume":"11","author":"Alizadeh Aghdam","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-9255-10-22","article-title":"Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration","volume":"10","author":"Kasperska-Zajac","year":"2013","journal-title":"J Inflamm (Lond)"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5415\/apallergy.0000000000000132","article-title":"A prospective observational study correlating possible novel biomarkers with disease severity and antihistamine response in chronic spontaneous urticaria","volume":"14","author":"Bhatia","year":"2024","journal-title":"Asia Pac Allergy"},{"issue":"3","key":"10.1016\/j.anai.2026.08.033_bib0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jdermsci.2013.03.003","article-title":"Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria","volume":"70","author":"Metz","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/ejd.2024.4600","article-title":"Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review","volume":"34","author":"Gimenez-Arnau","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"14","key":"10.1016\/j.anai.2026.08.033_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411328","article-title":"Biomarkers for monitoring treatment response of omalizumab in patients with chronic urticaria","volume":"24","author":"Pedersen","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.anai.2026.08.033_bib0025","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jaci.2021.02.038","article-title":"The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes","volume":"147","author":"Johal","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.08.033_bib0026","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","article-title":"Update on the treatment of chronic spontaneous urticaria","volume":"85","author":"Kolkhir","year":"2025","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.anai.2026.08.033_bib0027","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/ijd.13668","article-title":"Patient-reported outcomes (PROs) in chronic urticaria","volume":"56","author":"Moestrup","year":"2017","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.08.033_bib0028","first-page":"997","article-title":"The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2026.08.033_bib0029","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.08.033_bib0030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1398-9995.2005.00833.x","article-title":"A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria Quality of Life Questionnaire (CU-QoL)","volume":"60","author":"Baiardini","year":"2005","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.anai.2026.08.033_bib0031","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1398-9995.2011.02695.x","article-title":"Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q2oL","volume":"66","author":"Dias","year":"2011","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2026.08.033_bib0032","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1398-9995.2009.02132.x","article-title":"EAACI\/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria","volume":"64","author":"Konstantinou","year":"2009","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2026.08.033_bib0033","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jdv.15640","article-title":"Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria","volume":"33","author":"Yu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2026.08.033_bib0034","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaci.2008.11.040","article-title":"Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria","volume":"123","author":"Metz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.08.033_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.742470","article-title":"What basophil testing tells us about CSU patients - results of the CORSA study","volume":"12","author":"Marcelino","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.08.033_bib0036","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/2229-5178.202266","article-title":"Autologous serum and plasma skin tests in chronic spontaneous urticaria: a reappraisal","volume":"8","author":"Kumaran","year":"2017","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0037","doi-asserted-by":"crossref","first-page":"4","DOI":"10.23822\/EurAnnACI.1764-1489.238","article-title":"35 years of autologous serum skin test in chronic spontaneous urticaria: what we know and what we do not know","volume":"55","author":"Asero","year":"2023","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2026.08.033_bib0038","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0039","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaci.2025.04.004","article-title":"Endotypes of chronic spontaneous urticaria and angioedema","volume":"156","author":"Wong","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.08.033_bib0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.anai.2024.10.026","article-title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine","volume":"134","author":"Lang","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2025.10.025","article-title":"Understanding IgE-mediated autoimmunity and autoallergy","volume":"157","author":"Mo\u00f1ino-Romero","year":"2026","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0042","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.anai.2026.08.033_bib0043","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4168\/aair.2024.16.6.626","article-title":"Distinct clinical profiles of IgE and IgG autoantibodies to thyroid peroxidase in chronic spontaneous urticaria","volume":"16","author":"Jang","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0044","doi-asserted-by":"crossref","first-page":"53","DOI":"10.15386\/mpr-1598","article-title":"Comparison of immunoglobulin E anti-thyroid peroxidase antibodies in patients with Hashimoto thyroiditis and chronic spontaneous urticaria","volume":"94","author":"\u00c7ilda\u011f","year":"2021","journal-title":"Med Pharm Rep."},{"issue":"4","key":"10.1016\/j.anai.2026.08.033_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase\u2013a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2026.08.033_bib0046","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fimmu.2018.00689","article-title":"Immunoglobulin E-mediated autoimmunity","volume":"9","author":"Maurer","year":"2018","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.anai.2026.08.033_bib0047","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction in J Invest Dermatol. 2015;135(1):67-75]","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2026.08.033_bib0048","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria [published correction in N Engl J Med. 2013;368(24):2340-2341]","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0049","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol."},{"issue":"10450","key":"10.1016\/j.anai.2026.08.033_bib0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","article-title":"Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment","volume":"404","author":"Zuberbier","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.anai.2026.08.033_bib0051","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2026.08.033_bib0052","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.anai.2026.08.033_bib0053","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.anai.2026.08.033_bib0054","doi-asserted-by":"crossref","unstructured":"Gunnarsson I, Lindholm A, Petkovic M, Brolin S, B\u00f6rjesson O, Al Azzawi I, et al. Avacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden. Scand J Rheumatol. [e-pub ahead of print]. https:\/\/doi.org\/10.1080\/03009742.2026.2640767.","DOI":"10.1080\/03009742.2026.2640767"},{"key":"10.1016\/j.anai.2026.08.033_bib0055","article-title":"Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1016\/j.anai.2026.08.033_bib0056","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1182\/bloodadvances.2025017004","article-title":"Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis","volume":"9","author":"Hockman","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.anai.2026.08.033_bib0057","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.3390\/jcm15114217","article-title":"Efficacy and safety of treatments for paroxysmal nocturnal hemoglobinuria: a systematic literature review","volume":"15","author":"Gandhi","year":"2026","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.anai.2026.08.033_bib0058","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/bjd\/ljaf398","article-title":"Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial","volume":"194","author":"Giamarellos-Bourboulis","year":"2026","journal-title":"Br J Dermatol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626004485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626004485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:19:22Z","timestamp":1791260362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626004485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"alternative-id":["S1081120626004485"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.08.033","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement C5 defines 2 chronic spontaneous urticaria endotypes with distinct autoantibody profiles and omalizumab responses: The INCA study","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}